J&J (JNJ) Gets FDA Nod for Twice-Yearly Schizophrenia Drug
J&J (JNJ) gets FDA approval for its twice-a-year treatment option for schizophrenia patients, Invega Hafyera.
Johnson & Johnson JNJ announced that the FDA has approved another long-acting formulation of its antipsychotic drug, paliperidone palmitate, Invega Hafyera, for treating schizophrenia in adults.
Invega Hafyera is a long-acting injectable treatment, which will be administered every six months. The new long-acting formulation results in continuous treatment and symptom control over six months. The drug is the first and only FDA-approved twice-a-year treatment for schizophrenia. It offers schizophrenia patients the fewest doses per year for their treatment.
Please note that two other formulations of paliperidone palmitate — Invega Sustenna and Invega Trinza — are already approved to treat schizophrenia. While Invega Sustenna needs to be administered every month, Invega Trinza is administered once every three months. We note that a tablet formulation of paliperidone, Invega, was the first to receive FDA approval as acute and maintenance treatment of schizophrenia in 2006. It needs to be administered every day.
J&J has come a long way over the last 15 years in developing improved treatment options which significantly improves convenience for schizophrenia patients. The reduced administrations will help patients control their disorder with a better treatment plan.
Image Source: Zacks Investment Research
This year so far, J&J’s shares have risen 10.4% compared with an increase of 15.4% for the industry.
The approval of Invega Hafyera was based on data from a global phase III study that evaluated Invega Hafyera for non-inferiority compared to Invega Trinza. Data from the study demonstrated that 92.5% of patients who were administered Invega Hafyera were relapse-free at 12 months compared to 95% for Invega Trinza. The safety profile of Invega Hafyera was consistent with the safety profile of Invega Sustenna and Invega Trinza observed in previous studies.
Meanwhile, we note that J&J’s Invega franchise has maintained strong growth over the past few years. Worldwide sales from this franchise were almost $2 billion in the first half of 2021, gaining more than 10% year over year.
However, as Invega Sustenna and Invega Trinza get older, the risk of generics rises. Several generic-makers including Teva TEVA, Viatris VTRS, and Mallinckrodt Pharmaceuticals are trying to get approval for the generic version of either of these two drugs. J&J has initiated litigations against these companies to retain patent exclusivity. Moreover, the approval of Invega Hafyera provides long-term protection to J&J’s sales from the Invega franchise as it will have a longer patent exclusivity.
Zacks Rank & Stock to Consider
J&J currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A better-ranked stock from the biotech sector is Regeneron REGN, which sports a Zacks Rank #1.
Regeneron’s earnings per share estimates have moved north from $49.96 to $54.15 for 2021 and from $40.91 to $44.11 for 2022 in the past 30 days. The stock has risen 41% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.Click here for the 4 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report
Viatris Inc. (VTRS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research